Melanoma Stage III Clinical Trials

17 recruiting

Melanoma Stage III Trials at a Glance

21 actively recruiting trials for melanoma stage iii are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Tampa, Philadelphia, and New York. Lead sponsors running melanoma stage iii studies include H. Lee Moffitt Cancer Center and Research Institute, Philogen S.p.A., and Hildur Helgadottir.

Browse melanoma stage iii trials by phase

Treatments under study

About Melanoma Stage III Clinical Trials

Looking for clinical trials for Melanoma Stage III? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Melanoma Stage III trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Melanoma Stage III clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 2Phase 3

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Unresectable MelanomaCutaneous MelanomaMelanoma (Skin Cancer)+1 more
Linnaeus Therapeutics, Inc.135 enrolled9 locationsNCT06624644
Recruiting
Phase 2

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Melanoma Stage IVInoperable DiseaseMelanoma Stage III
H. Lee Moffitt Cancer Center and Research Institute29 enrolled1 locationNCT04562129
Recruiting
Phase 2

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

MelanomaAdvanced MelanomaMelanoma Stage IV+1 more
H. Lee Moffitt Cancer Center and Research Institute90 enrolled1 locationNCT06295159
Recruiting
Phase 1Phase 2

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Metastatic MelanomaMelanoma Stage IVMelanoma Stage III+1 more
Perspective Therapeutics300 enrolled13 locationsNCT05655312
Recruiting
Phase 2

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

MelanomaMelanoma Stage IVMelanoma (Skin)+1 more
University of California, Irvine14 enrolled1 locationNCT06771544
Recruiting
Early Phase 1

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IVBRAF V600 MutationMelanoma Stage III
H. Lee Moffitt Cancer Center and Research Institute50 enrolled1 locationNCT04741997
Recruiting

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

MelanomaUnresectable MelanomaMelanoma Stage IV+1 more
University of Wisconsin, Madison24 enrolled1 locationNCT06199713
Recruiting
Phase 3

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Melanoma Stage IIIBMelanoma Stage IIICMelanoma Stage IIID
Philogen S.p.A.186 enrolled37 locationsNCT03567889
Recruiting
Phase 3

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

Malignant Melanoma Stage III
Hildur Helgadottir128 enrolled3 locationsNCT06794775
Recruiting
Not Applicable

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Melanoma Stage IVPediatric ALLMelanoma Stage III+4 more
Miltenyi Biomedicine GmbH40 enrolled7 locationsNCT06508775
Recruiting
Not Applicable

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Melanoma Stage IVMelanoma Stage III
Kelly McMasters30 enrolled1 locationNCT04513028
Recruiting
Phase 2

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Melanoma Stage IVMelanoma Stage III
University of California, San Francisco25 enrolled2 locationsNCT04598009
Recruiting
Phase 1

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

MelanomaMelanoma Stage IVMelanoma Stage III
Inge Marie Svane10 enrolled2 locationsNCT06204991
Recruiting
Phase 1Phase 2

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

CancerCutaneous MelanomaMelanoma Stage IV+1 more
Krystal Biotech, Inc.240 enrolled15 locationsNCT05970497
Recruiting
Phase 1Phase 2

FMT to Convert Response to Immunotherapy

Melanoma Stage IVMelanoma Stage III
The Netherlands Cancer Institute24 enrolled1 locationNCT05251389
Recruiting
Not Applicable

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

ImmunotherapyMelanoma Stage IVMelanoma Stage III+1 more
Erasmus Medical Center80 enrolled1 locationNCT05652673
Recruiting

Versatile Ampification Single-Molecule Detection in Liquid Biopsy

Melanoma Stage IVMelanoma (Skin)Melanoma Stage III+1 more
Regina Elena Cancer Institute20 enrolled1 locationNCT05940311
Recruiting
Phase 2

NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

Melanoma Stage IIIB-IV
Oslo University Hospital27 enrolled1 locationNCT06651151
Recruiting
Phase 2

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Melanoma Stage IVMelanoma Stage III
Philogen S.p.A.162 enrolled1 locationNCT06284590
Recruiting

MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns]

Melanoma (Skin)Melanoma Stage III
Russian Academy of Medical Sciences72 enrolled1 locationNCT06299878